Tom Croce is vice president for global patient advocacy at bluebird bio, inc., the clinical-stage biotech company that develops gene therapies for severe genetic and rare diseases. He and his team are responsible for identification and integration of patient perspectives across the entire development and commercial continuum, while ensuring meaningful company representation to patient, caregiver and advocate partners around the world. Tom also oversees the company’s efforts to educate and activate the advocacy community on the transformative nature of regenerative medicine.
Prior to joining bluebird, Tom was vice president, global advocacy relations for Amgen Inc. There he designed and oversaw a new advocacy relations function with responsibility for activating patient groups, consumer organizations, medical societies and professional associations across the company’s significant portfolio of both marketed and experimental medicines. His enterprise-wide vision, designed and executed with a 21-member team, resulted in business-critical partnerships that focused on access to therapies and disease education and awareness.
